JAMA Network
About The Study: The findings of this study suggest that glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy is associated with a higher risk of smell and taste disturbance, highlighting the need for closer monitoring and greater public health awareness. Future research is required to validate these findings and to further explore the mechanisms underlying this association.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
